The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1098
February 19, 2001
View Complete Issue         Table of Contents 2019 
Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis
February 19, 2001 (Issue: 1098)
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein thrombosis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis
Article code: 1098b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.